Compass Therapeutics stock rating reiterated as Market Outperform by Citizens

Citizens reiterated a Market Outperform rating on Compass Therapeutics after the company reported pipeline progress and top-line tovecimig monotherapy results in metastatic colorectal cancer.

Citizens reiterated a Market Outperform rating on Compass Therapeutics following a corporate update and the release of an ASCO GI abstract reporting top-line tovecimig monotherapy results in metastatic colorectal cancer. The company reported progress across its clinical-stage pipeline and noted upcoming readouts. Citizens highlighted anticipated top-line progression-free survival and overall survival data for tovecimig, which the article says will be followed by regulatory discussions. The company also announced executive appointments effective January 1, 2026. Key facts: - The article reports that Citizens reiterated its Market Outperform rating after the corporate update and ASCO GI abstract release. - Compass Therapeutics is reported to be on track for key survival analyses for tovecimig in biliary tract cancer by late Q1 2026. - The article notes a reported 243% share return over the past year and that the company held about $209 million in cash with a current ratio of 17.82. - The article mentions a third response to the PD-1 x PD-L1 bispecific antibody CTX-8371 in a patient with Hodgkin lymphoma and a durable partial response in a triple-negative breast cancer patient through 32 weeks. - The article reports executive appointments of a Chief Commercial Officer and a Chief Medical Officer effective January 1, 2026. - The article mentions that other analysts, including Stifel, Raymond James, and William Blair, provided Outperform coverage in recent notes. Summary: The article describes analyst attention following recent clinical updates and an ASCO GI abstract for tovecimig. Upcoming top-line survival readouts and subsequent regulatory discussions are noted as the next milestones for the program.